Jupiter Neurosciences announced the official commercial launch of Nugevia, its consumer longevity product line, a pivotal milestone in the neuro-inflammation biotech’s strategy to generate near-term revenue while maintaining momentum in its clinical pipeline.
Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary Jotrol micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space.
Nugevia's first three formulations — targeting mitochondrial support, mental clarity and ‘beauty from within; — will be sold via a direct-to-consumer model starting in Q3 2025. Each product integrates Jotrol, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials.
The Jotrol platform is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Back in February, Catalent inked a deal to manufacture the softgel capsules for Jupiter’s upcoming phase 2a clinical trial in Parkinson’s disease.
Jupiter IPO-ed late last year, raising $11 million for the unique resveratrol platform product, primarily targeting treatment of neuro-inflammation.